Stock ALVO ALVOTECH
Add to a list
To use this feature you must be a member
Log inSign up

Company Alvotech Nyse

Equities

ALVO

LU2458332611

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
12.89 USD +0.70% Intraday chart for Alvotech +7.74% +37.42%
Apr. 17 Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab) CI
Apr. 16 Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis MT

Business Summary

Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company's pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Number of employees: 999

Sales per Business

USD in Million2022Weight2023Weight Delta
Biosimilar Medicines
100.0 %
83 100.0 % 91 100.0 % +10.12%

Sales per region

USD in Million2022Weight2023Weight Delta
Europe
69.5 %
39 47.5 % 64 69.5 % +61.06%
North America
20.0 %
31 37.1 % 18 20.0 % -40.53%
Asia and Other
10.5 %
0 0.0 % 10 10.5 % -

Managers

Managers TitleAgeSince
Vilhelm Wessman CEO
 Chief Executive Officer 54 18-11-01
Joel Morales DFI
 Director of Finance/CFO 46 20-01-31
Giedrius Zunda CTO
 Chief Tech/Sci/R&D Officer - 22-12-31
Joseph E. McClellan CTO
 Chief Tech/Sci/R&D Officer 50 19-09-30
Faysal Kalmoua COO
 Chief Operating Officer 48 20-05-31
Benedikt Stefansson IRC
 Investor Relations Contact - 22-03-01
Ming Li PRN
 Corporate Officer/Principal 47 -
Anil Okay PRN
 Corporate Officer/Principal 38 -
Helga Zharov LAW
 General Counsel 57 20-04-30

Members of the board

Members of the board TitleAgeSince
Linda McGoldrick BRD
 Director/Board Member 68 22-06-15
Helga Zharov LAW
 General Counsel 57 20-04-30
Vilhelm Wessman CEO
 Chief Executive Officer 54 18-11-01
Tomas Ekman BRD
 Director/Board Member 56 18-12-31
Richard Davies BRD
 Director/Board Member 62 18-12-31
Árni Harðarson BRD
 Director/Board Member 57 22-06-15
Lisa Graver BRD
 Director/Board Member 53 22-06-15
Faysal Kalmoua COO
 Chief Operating Officer 48 20-05-31
Ann Merchant BRD
 Director/Board Member 59 22-06-15

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 266,821,844 72,673,643 ( 27.24 %) 0 27.24 %

Shareholders

NameEquities%Valuation
Aztiq Pharma Partners SARL
37.91 %
101,165,374 37.91 % 1 236 M $
Celtic Holdings SCA
33.73 %
90,005,334 33.73 % 1 100 M $
YAS Holding
2.796 %
7,459,485 2.796 % 91 M $
Oaktree Capital Management LP
2.043 %
5,450,896 2.043 % 67 M $
Struengmann Family
1.771 %
4,724,340 1.771 % 58 M $
FUJI PHARMA CO., LTD.
1.677 %
4,475,691 1.677 % 55 M $
Bracebridge Capital LLC
1.634 %
4,360,524 1.634 % 53 M $
Vanguard Fiduciary Trust Co.
1.148 %
3,061,836 1.148 % 37 M $
BAXTER INTERNATIONAL INC.
1.025 %
2,735,145 1.025 % 33 M $
Shinhan Securities Co., Ltd. (Private Banking)
0.5591 %
1,491,897 0.5591 % 18 M $
NameEquities%Valuation
Oaktree Capital Management LP
-
4,666,667 - 20 M $
LMR Partners LLP
-
350,629 - 2 M $
Linden Advisors LP
-
273,380 - 1 M $
Moore Capital Management LP
-
125,000 - 535 625 $
Sculptor Capital LP
-
100,000 - 428 500 $
Kim LLC
-
75,000 - 321 375 $
Arena Capital Advisors LLC
-
69,471 - 297 683 $
Boussard & Gavaudan Investment Management LLP
-
62,500 - 267 813 $
Athos Capital Ltd.
-
38,075 - 163 151 $
HRT Financial LLC
-
23,672 - 101 435 $

Company contact information

Alvotech

9, rue de Bitbourg

1273, Luxembourg

+

http://www.alvotech.com
address Alvotech(ALVO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Alvotech

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.8 USD
Average target price
16.5 USD
Spread / Average Target
+28.91%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.82% 41.36B
LONZA GROUP AG Stock Lonza Group AG
+44.25% 41.3B
MODERNA, INC. Stock Moderna, Inc.
+2.56% 39.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 25.62B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+3.09% 24.09B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.16% 18.38B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+22.12% 11.85B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.74% 11.82B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.75% 11.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALVO Stock
  4. ALVO Stock
  5. Company Alvotech